Access to anti-retroviral drugs, male in Liberia

Liberia: Access to anti-retroviral drugs, male was 86.0% in 2024. ◆ Volatile

Latest (2024)
86.0%
Change on year
up 13.2%
World rank
30th
of 141 countries
All-time high
86.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Liberia, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 3 %2007: 4 %2008: 5 %2009: 8 %2010: 12 %2011: 14 %2012: 11 %2013: 12 %2014: 13 %2015: 17 %2016: 15 %2017: 18 %2018: 28 %2019: 31 %2020: 39 %2021: 51 %2022: 64 %2023: 76 %2024: 86 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Liberia stood at 86.0%. That is the highest value across all 25 years on record.

The figure is up 13.2% on the previous year and up 561.5% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Liberia peaked at 86.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Liberia 30th out of 141 countries with data for 2024, putting it in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Liberia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Liberia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 3.0%
2007 4.0% +33.3%
2008 5.0% +25.0%
2009 8.0% +60.0%
2010 12.0% +50.0%
2011 14.0% +16.7%
2012 11.0% -21.4%
2013 12.0% +9.1%
2014 13.0% +8.3%
2015 17.0% +30.8%
2016 15.0% -11.8%
2017 18.0% +20.0%
2018 28.0% +55.6%
2019 31.0% +10.7%
2020 39.0% +25.8%
2021 51.0% +30.8%
2022 64.0% +25.5%
2023 76.0% +18.8%
2024 86.0% +13.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.0% 0.0% 8.0% 10
2010s 17.1% 11.0% 31.0% 10
2020s 63.2% 39.0% 86.0% 5

Countries ranked near Liberia

  1. 27 Ecuador 87.0% compare
  2. 27 Haiti 87.0% compare
  3. 27 Slovenia 87.0% compare
  4. 30 Singapore 86.0% compare
  5. 30 Thailand 86.0% compare
  6. 30 Togo 86.0% compare

See the full ranking of 160 places →

More gender data for Liberia

All data for Liberia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Liberia?
Access to anti-retroviral drugs, male in Liberia was 86.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Liberia?
The highest recorded value was 86.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Liberia?
The lowest recorded value was 0.0% in 2000.
How does Liberia rank for access to anti-retroviral drugs, male?
Liberia ranks 30th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Liberia?
Over the last ten years it is up 561.5%. The long-run trend across the full record is volatile.
Where does this Liberia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Liberia. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/liberia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/liberia/">Access to anti-retroviral drugs, male in Liberia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.